Treatment of Advanced Cutaneous Squamous Cell Carcinoma: A Mohs Surgery and Dermatologic Oncology Perspective

References

• De Vries E , VanDe Poll-Franse LV, LouwmanWJ, DeGruijl FR, CoeberghJWW. Predictions of skin cancer incidence in the Netherlands up to 2015. Br. J. Dermatol.152(3), 481–488 (2005).
   PubMed Web of Science ®Google Scholar
• Miller DL , WeinstockMA. Nonmelanoma skin cancer in the United States: incidence. J. Am. Acad. Dermatol.30(5), 774–778 (1994).
   PubMed Web of Science ®Google Scholar
• Green AC , OlsenCM. Cutaneous squamous cell carcinoma: an epidemiological review. Br. J. Dermatol.177(2), 373–381 (2017).
   PubMed Web of Science ®Google Scholar
• Our new approach to a challenging skin cancer statistic. The Skin Cancer Foundation (2021). www.skincancer.org/blog/our-new-approach-to-a-challenging-skin-cancer-statistic/
   Google Scholar
• Hacker SM , FlowersFP. Squamous cell carcinoma of the skin: will heightened awareness of risk factors slow its increase? In: Postgraduate Medicine115–126 (1993). https://pubmed.ncbi.nlm.nih.gov/8389446/
   Google Scholar
• Marks R . The epidemiology of non-melanoma skin cancer: who, why and what can we do about it. In: J.Dermatol.Blackwell Publishing Ltd, 853–857 (1995). https://pubmed.ncbi.nlm.nih.gov/8557858/
   Google Scholar
• Que SKT , ZwaldFO, SchmultsCD. Cutaneous squamous cell carcinoma: management of advanced and high-stage tumors. J. Am. Acad. Dermatol.78(2), 249–261 (2018).
   PubMed Web of Science ®Google Scholar
• Kallini JR , HamedN, KhachemouneA. Squamous cell carcinoma of the skin: epidemiology, classification, management, and novel trends. Int. J. Dermatol.54(2), 130–140 (2015).
   PubMed Web of Science ®Google Scholar
• Liu LS , ColegioOR. Molecularly targeted therapies for nonmelanoma skin cancers. Int. J. Dermatol.52(6), 654–665 (2013).
   PubMed Web of Science ®Google Scholar
• Jaju PD , RansohoffKJ, TangJY, SarinKY. Familial skin cancer syndromes increased risk of nonmelanotic skin cancers and extracutaneous tumors. J. Am. Acad. Dermatol.74(3), 437–451 (2016).
   PubMed Web of Science ®Google Scholar
• Skin cancer facts & statistics - The Skin Cancer Foundation (2021). www.skincancer.org/skin-cancer-information/skin-cancer-facts/
   Google Scholar
• Brodland DG , ZitelliJA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J. Am. Acad. Dermatol.27(2), 241–248 (1992).
   PubMed Web of Science ®Google Scholar
• Lansbury L , Bath-HextallF, PerkinsW, StantonW, Leonardi-BeeJ. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ347 (2013).
   Google Scholar
• Roenigk RK , RoenigkHH. Current surgical management of skin cancer in dermatology. J. Dermatol. Surg. Oncol.16(2), 136–151 (1990).
   PubMedGoogle Scholar
• Mohs FE . Chemosurgery for the microscopically controlled excision of cutaneous cancer. Head Neck Surg.1(2), 150–163 (1978).
   PubMedGoogle Scholar
• Alam M , RatnerD. Cutaneous squamous-cell carcinoma. N. Engl. J. Med.344(13), 975–983 (2001).
   PubMed Web of Science ®Google Scholar
• Minton TJ . Contemporary Mohs surgery applications. Curr. Opin. Otolaryngol. Head Neck Surg.16(4), 376–380 (2008).
   PubMed Web of Science ®Google Scholar
• Schmults CD , KariaPS, CarterJB, HanJ, QureshiAA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatology .149(5), 541–547 (2013).
   PubMed Web of Science ®Google Scholar
• Alam M , ArmstrongA, BaumCet al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J. Am. Acad. Dermatol.78(3), 560–578 (2018).
   PubMed Web of Science ®Google Scholar
• National comprehensive cancer network . Squamous cell skin cancer. Version 2 (2020).
   Google Scholar
• Brantsch KD , MeisnerC, SchönfischBet al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol.9(8), 713–720 (2008).
   PubMed Web of Science ®Google Scholar
• Burton KA , AshackKA, KhachemouneA. Cutaneous squamous cell carcinoma: a review of high-risk and metastatic disease. Am. J. Clin. Dermatol.17(5), 491–508 (2016).
   PubMed Web of Science ®Google Scholar
• Claveau J , ArchambaultJ, ErnstDSet al. Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma. Curr. Oncol.27(4), 399–407 (2020).
   PubMed Web of Science ®Google Scholar
• Migden MR , RischinD, SchmultsCDet al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N. Engl. J. Med.379(4), 341–351 (2018).
   PubMed Web of Science ®Google Scholar
• Migden MR , KhushalaniNI, ChangALSet al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, Phase 2, single-arm trial. Lancet Oncol.21(2), 294–305 (2020).
   PubMed Web of Science ®Google Scholar
• Rischin D , MigdenMR, LimAMet al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J. Immunother. Cancer8(1), 1–8 (2020).
   Web of Science ®Google Scholar
• Edwards L , BermanB, RapiniRPet al. Treatment of cutaneous squamous cell carcinomas by intralesional interferon Alfa-2b therapy. Arch. Dermatol.128(11), 1486–1489 (1992).
   PubMedGoogle Scholar
• Lippman SM , ParkinsonDR, ItriLMet al. 13-cis-retinoic acid and interferon α-2a: effective combination. Therapy for advanced squamous cell carcinoma of the skin. J. Natl Cancer Inst.84(4), 235–241 (1992).
   PubMedGoogle Scholar
• Dunn GP , OldLJ, SchreiberRD. The three Es of cancer immunoediting. Annu. Rev. Immunol.22, 329–360 (2004).
   PubMed Web of Science ®Google Scholar
• Jensen P , HansenS, MollerBet al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J. Am. Acad. Dermatol.40(2I), 177–186 (1999).
   PubMedGoogle Scholar
• Hartevelt MM , BouwesBavinck JN, KootteAMM, VermeerBJ, VandenbrouckeJP. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation49(3), 506–509 (1990).
   PubMed Web of Science ®Google Scholar
• Lindelöf B , SigurgeirssonB, GäbelH, SternRS. Incidence of skin cancer in 5356 patients following organ transplantation. Br. J. Dermatol.143(3), 513–519 (2000)
   PubMed Web of Science ®Google Scholar
• Webb MC , ComptonF, AndrewsPA, KoffmanGG. Skin tumors posttransplantation: a retrospective analysis of 28 years’ experience at a single centre. In: Transplantation Proceedings, Transplant Proc.828–830 (1997).
   Google Scholar
• Berg D , OtleyCC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J. Am. Acad. Dermatol.47(1), 1–20 (2002).
   PubMed Web of Science ®Google Scholar
• Guillebon de E . Anti program death-1/anti program death-ligand 1 in digestive cancers. World J. Gastrointest. Oncol.7(8), 95 (2015).
   PubMed Web of Science ®Google Scholar
• Lipson E , FordeP, HammersH, EmensLA, TaubeJM, TopalianSL. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin. Oncol.42(4), 587–600 (2015).
   PubMed Web of Science ®Google Scholar
• Wherry EJ . T cell exhaustion. Nat. Immunol.12(6), 492–499 (2011).
   PubMed Web of Science ®Google Scholar
• Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer12(4), 252–264 (2012).
   PubMed Web of Science ®Google Scholar
• Rizvi NA , HellmannMD, SnyderAet al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (80-.).348(6230), 124–128 (2015).
   PubMed Web of Science ®Google Scholar
• Chalmers ZR , ConnellyCF, FabrizioDet al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med.9(1), (2017)
   Google Scholar
• Chan TA , WolchokJD, SnyderA. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med.373(20), 1984–1984 (2015).
   PubMed Web of Science ®Google Scholar
• FDA approves cemiplimab-rwlc for metastatic or locally advanced cutaneous squamous cell carcinoma | FDA (2019). www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-cemiplimab-rwlc-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma
   Google Scholar
• Libtayo® (cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union (2019). www.prnewswire.com/news-releases/libtayo-cemiplimab-approved-for-advanced-cutaneous-squamous-cell-carcinoma-in-the-european-union-300878561.html
   Google Scholar
• Study of REGN2810 in patients with advanced cutaneous squamous cell carcinoma – Full Text View – ClinicalTrials.gov (2016). https://clinicaltrials.gov/ct2/show/NCT02760498
   Google Scholar
• Study of REGN2810 (Anti-PD-1) in patients with advanced malignancies – Full Text View – ClinicalTrials.gov (2015). https://clinicaltrials.gov/ct2/show/NCT02383212
   Google Scholar
• Migden MR , KhushalaniNI, ChangALSet al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, Phase 2, single-arm trial. Lancet Oncol.21(2), 294–305 (2020).
   PubMed Web of Science ®Google Scholar
• Rischin D , KhushalaniN, SchmultsCet al. Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (cSCC): follow-up at 43months. 10th World Congr. Melanoma Conjunction with 17th EADO Congr.321–322 (2021). www.abstractserver.com/wcm2021/ebook/#322
   Google Scholar
• FDA approves pembrolizumab for cutaneous squamous cell carcinoma | FDA (2020). www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-cutaneous-squamous-cell-carcinoma
   Google Scholar
• Grob JJ , GonzalezR, Basset-SeguinNet al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm Phase II trial (KEYNOTE-629). In: J. Clin. Oncol, American Society of Clin. Oncol.2916–2925 (2020). https://pubmed.ncbi.nlm.nih.gov/32673170/
   Google Scholar
• Hughes B , Munoz-CouseloE, MortierL, BratlandA, GutzmerR, RoshdyO. CT006 - Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629. Am. Assoc. Cancer Res. Annu. Meet. (2021). www.abstractsonline.com/pp8/#!/9325/presentation/5137
   Google Scholar
• Grob J , Munoz-CouseloE, MortierLet al. KEYNOTE 629: Phase 2 study of pembrolizumab monotherapy for lcoally advanced or recurrent/metastatic cutaneous squamous cell carcinoma. 10th World Congr. Melanoma Conjunction with 17th EADO Congr.322–323 (2021). www.abstractserver.com/wcm2021/ebook/#322
   Google Scholar
• Day F , KumarM, FentonL, GedyeC. Durable response of metastatic squamous cell carcinoma of the skin to Ipilimumab immunotherapy. J. Immunother.40(1), 36–38 (2017).
   PubMed Web of Science ®Google Scholar
• Khansur T , KennedyA. Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer67(8), 2030–2032 (1991).
   PubMed Web of Science ®Google Scholar
• Sadek H , AzliN, WendlingJLet al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fuorouracil, and bleomycin.
   Google Scholar
• Shin D , GlissonB, KhuriFet al. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J. Clin. Oncol.20(2), 364–370 (2002).
   PubMed Web of Science ®Google Scholar
• Porceddu S , BresselM, PoulsenMet al. Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized Phase III TROG 05.01 Trial. J. Clin. Oncol.36(13), 1275–1283 (2018).
   PubMed Web of Science ®Google Scholar
• Singh D , KumarAttri B, KaurGill R, BariwalJ. Review on EGFR Inhibitors: critical updates. Mini-Reviews Med. Chem.16(14), 1134–1166 (2016).
   PubMed Web of Science ®Google Scholar
• Galer CE , CoreyCL, WangZet al. Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head Neck33(2), 189–198 (2011).
   PubMed Web of Science ®Google Scholar
• Maubec E , PetrowP, Scheer-SenyarichIet al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J. Clin. Oncol.29(25), 3419–3426 (2011).
   PubMed Web of Science ®Google Scholar
• Harari PM . Epidermal growth factor receptor inhibition strategies in oncology. Endocr. Relat. Cancer11(4), 689–708 (2004).
   PubMed Web of Science ®Google Scholar
• Foote MC , McGrathM, GuminskiAet al. Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann. Oncol.25(10), 2047–2052 (2014).
   PubMed Web of Science ®Google Scholar
• William WN , FengL, FerrarottoRet al. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: a single-arm Phase II clinical trial. J. Am. Acad. Dermatol.77(6), 1110–1113.e2 (2017).
   PubMed Web of Science ®Google Scholar
• Gold KA , KiesMS, WilliamWN, JohnsonFM, LeeJJ, GlissonBS. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm Phase 2 clinical trial. Cancer124(10), 2169–2173 (2018).
   PubMed Web of Science ®Google Scholar
• Fabbrocini G , PanarielloL, CaroG, CacciapuotiS. Acneiform rash induced by EGFR inhibitors: review of the literature and new insights. Ski. Appendage Disord.1(1), 31–37 (2015).
   PubMedGoogle Scholar
• Morgan GW . A synopsis of radiation oncology in Australia, with particular reference to New South Wales. Aust. N. Z. J. Surg.68(3), 225–235 (1998).
   PubMedGoogle Scholar
• Cognetta AB , HowardBM, HeatonHP, StoddardER, HongHG, GreenWH. Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients. J. Am. Acad. Dermatol.67(6), 1235–1241 (2012).
   PubMed Web of Science ®Google Scholar
• Abbatucci JS , BoulierN, LaforgeT, LozierJC. Radiation therapy of skin carcinomas: results of a hypofractionated irradiation schedule in 675 cases followed more than 2 years. Radiother. Oncol.14(2), 113–119 (1989).
   PubMed Web of Science ®Google Scholar
• Hernández-Machin B , BorregoL, Gil-garcíaM, HernándezBH. Office-based radiation therapy for cutaneous carcinoma: evaluation of 710 treatments. Int. J. Dermatol.46(5), 453–459 (2007).
   PubMed Web of Science ®Google Scholar
• Schulte KW , LippoldA, AurasCet al. Soft x-ray therapy for cutaneous basal cell and squamous cell carcinomas. J. Am. Acad. Dermatol.53(6), 993–1001 (2005).
   PubMed Web of Science ®Google Scholar
• Cranmer LD , EngelhardtC, MorganSS. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist15(12), 1320–1328 (2010).
   PubMed Web of Science ®Google Scholar
• Jarkowski A , HareR, LoudPet al. Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): The Roswell Park experience and a review of the Literature. Am. J. Clin. Oncol. Cancer Clin. Trials39(6), 545–548 (2016).
   PubMed Web of Science ®Google Scholar
• Wood LS , RN, MSN, OCN. Immune-related adverse events from immunotherapy: incorporating care step pathways to improve management across tumor types. J. Adv. Pract. Oncol.10(2), 47 (2019).
   PubMedGoogle Scholar
• Lala M , AkalaO, ChartashEet al. Abstract CT042: Pembrolizumab 400 mg Q6W dosing: first clinical outcomes data from Keynote-555 cohort B in metastatic melanoma patients. In: Cancer Research, American Association for Cancer Research (AACR).CT042–CT042 (2020). https://cancerres.aacrjournals.org/content/80/16_Supplement/CT042
   Google Scholar
• Lai HC , LinJF, HwangTIS, LiuYF, YangAH, WuCK. Programmed cell death 1 (PD-1) inhibitors in renal transplant patients with advanced cancer: a double-edged sword?Int. J. Mol. Sci.20(9), 2194 (2019).
   PubMed Web of Science ®Google Scholar
• Kumar V , ShinagareAB, RennkeHGet al. The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature. Oncologist25(6), 505–514 (2020).
   PubMed Web of Science ®Google Scholar
• Tsung I , WordenFP, FontanaRJ. A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma. Oncologist26(2), 133–138 (2021).
   PubMed Web of Science ®Google Scholar
• Postow M , SidlowR, HellmannM. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med.378(2), 158–168 (2018).
   PubMed Web of Science ®Google Scholar
• Brahmer J , LacchettiC, SchneiderBet al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol.36(17), 1714–1768 (2018).
   PubMed Web of Science ®Google Scholar
• Thompson JA , SchneiderBJ, BrahmerJet al. NCCN Guidelines Version 3.2021 Management of immunotherapy-related toxicities NCCN guidelines panel disclosures continue NCCN (2021). www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf
   Google Scholar
• De Gruijl TD , JanssenAB, Van BeusechemVW. Arming oncolytic viruses to leverage antitumor immunity.Expert Opin. Biol. Ther.15(7), 959–971 (2015).
   PubMed Web of Science ®Google Scholar
• Trembley JH , UngerGM, KormanVLet al. Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells. Cancer Lett.315(1), 48–58 (2012).
   PubMed Web of Science ®Google Scholar
• Trembley JH , ChenZ, UngerGet al. Emergence of protein kinase CK2 as a key target in cancer therapy. BioFactors36(3), 187–195 (2010).
   PubMed Web of Science ®Google Scholar
• Götz C , GratzA, KucklaenderU, JoseJ. TF – A novel cell-permeable and selective inhibitor of human protein kinase CK2 induces apoptosis in the prostate cancer cell line LNCaP. Biochim. Biophys. Acta – Gen. Subj.1820(7), 970–977 (2012).
   Web of Science ®Google Scholar
• Siddiqui-Jain A , DryginD, StreinerNet al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res.70(24), 10288–10298 (2010).
   PubMed Web of Science ®Google Scholar
• Cannon CM , TrembleyJH, KrenBTet al. Evaluation of protein kinase CK2 as a therapeutic target for squamous cell carcinoma of cats. Am. J. Vet. Res.78(8), 946–955 (2017).
   PubMed Web of Science ®Google Scholar
• Unger GM , KrenBT, KormanVLet al. Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma. Mol. Cancer Ther.13(8), 2018–2029 (2014).
   PubMed Web of Science ®Google Scholar